IntoCell, Inc.

As of June 30, 2026, IntoCell, Inc. carries a market capitalization of 357.52B, placing it among publicly traded companies globally. Its enterprise value stands at 343.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, IntoCell, Inc. has 15.02M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 111.60, and the price-to-book ratio stands at 18.19.

These figures are as of June 30, 2026. The EV/Sales ratio of 107.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 343.82B versus a market cap of 357.52B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, IntoCell, Inc. maintains a current ratio of 1.85, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.02, indicating elevated leverage, while an interest coverage ratio of -28.55 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, IntoCell, Inc. posted a negative return on equity (ROE) of -42.15, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.35, reflecting losses generated across the asset base. The company generates approximately 75.11M in revenue per employee across its workforce of 42.50, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, IntoCell, Inc.'s stock has declined approximately 63.20% over the past 52 weeks. The 50-day moving average sits at 17,927.40, while the 200-day moving average is 32,675.40.

Over the twelve months ended June 30, 2026, IntoCell, Inc. generated 3.19B in revenue and converted that into -9.45B in net income, yielding earnings per share of -631.09. EBITDA reached -8.11B, while operating income came in at -8.91B.

As of June 30, 2026, IntoCell, Inc. holds 23.93B in cash and equivalents against 10.23B in total debt, resulting in a net debt position of -607.89M. Total book value stands at 19.66B, with working capital of 11.48B providing operational flexibility.

IntoCell, Inc. produced -10.18B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -932.04M in capital expenditures, free cash flow totaled -11.12B - equivalent to -742.72 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -279.02 and net profit margin of -295.93 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.76, meaning IntoCell, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, IntoCell, Inc. has an Altman Z-Score of 8.08, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.